Samsung Biologics discontinues arbitration proceedings against Biogen Samsung and Biogen to operate biosimilar business separately
Translated by Kim So-in 공개 2022-03-25 08:06:54
이 기사는 2022년 03월 25일 08:00 thebell 에 표출된 기사입니다.
Samsung Biologics, the biotech arm of South Korea's Samsung Group, has discontinued the International Chamber of Commerce (ICC) arbitration proceedings against U.S.-based Biogen Therapeutics.The two companies have had a dispute over a non-compete clause signed during their establishment of biosimilar joint venture Samsung Bioepis and started to seek arbitration from the ICC in 2020.
Samsung Biologics said in its report that the company and Biogen stopped the arbitration proceedings filed with the International Court of Arbitration. They reached a settlement in February, following Samsung Biologics’ deal with Biogen in January to buy the U.S. drugmaker's entire stake in Samsung Bioepis.
The arbitration began as the two companies had a disagreement over the non-compete clause in their joint venture agreement to establish Samsung Bioepis in 2011. In 2020, Biogen requested arbitration in the International Chamber of Commerce Court of International Arbitration, seeking interpretation of certain provisions in agreement that the two companies would not engage in independent biosimilar drug business.
With the arbitration case resolved through settlement, Samsung Biologics’ acquisition of Samsung Bioepis is expected to accelerate. Samsung Biologics and Biogen plan to expand their own biosimilar businesses once the Sasmung Bioepis deal is closed in April.
In April 2021, Biogen and China’s Bio-Thera Solutions announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA.
Samsung Bioepis is selling five biosimilars, which are Infliximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab. The company plans to double the number of its biosimilar products on sale to 10 by 2025.
Even after the transaction is closed, Samsung and Biogen will continue to work closely, according to an official of Samsung Biologics. (Reporting by Eun-su Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '푸드테크에 진심' 롯데벤처스, 투자재원 확충 시동
- [thebell interview/비상하는 K-우주항공 스타트업]박동하 “코스모비로 우주와 인간 가까워지기를”
- [모태 2024 2차 정시출자]‘AC전용' 스포츠출발, 상상이비즈 '연속 GP' 도전
- '오스템임플란트 볼트온' MBK-UCK, 브라질 임플란트 3위 업체 인수
- '주주환원 강화' 케이카, 1분기 실적 주목
- 가보지 않은 길 'ARC' 셀비온-앱티스 맞손, 독성에 도전
- [여전사경영분석]BNK캐피탈, 순익 반등에도 수익성 제고 과제 여전히
- [은행경영분석]권재중 BNK금융 CFO 첫 성적표 'CET1 12%대' 진입
- 마이금융파트너, 신계약 성과에 2년째 매출 급증
- [여전사경영분석]문동권식 수익다변화 전략 적중…신한카드, 순익 회복 시동